Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

Presentation

A Robust and Flexible Baculovirus-Insect Cell System for AAV Vector Production with Improved Yield, Capsid Ratios and Potency

Download PDF